Saverna Therapeutics AG

Saverna Therapeutics is a Swiss pharmaceutical start-up company founded in 2017 with the focus on developing small molecule drugs to target non-coding RNA for treating diseases with high unmet need. Founded by four former lab heads at Novartis, Switzerland, the company aims to leverage their expertise in a specialized and validated drug discovery platform tailored for identifying RNA-targeting small molecule compounds. The company's activities have the potential to impact the development of a new field in drug discovery by utilizing an innovative and advanced platform for identifying small molecule drugs targeting non-coding RNA, a novel class of drug targets.

Saverna Therapeutics aims to discover highly active, selective, and cell-permeable molecules to target RNA biology. The company focuses on disease areas of inflammation, cancer, and infection. With a recent Venture Round investment from Viva BioInnovator on 01 January 2020, the company is poised to advance its drug discovery efforts and potentially bring new and impactful treatments to the market.